Multicentre US trials for Healos bone graft:
This article was originally published in Clinica
Executive Summary
Swiss company Sulzer Medica has begun a US multicentre clinical trial of Orquest's Healos bone graft substitute used in combination with Sulzer's BAK interbody fusion device, following positive preliminary trial results. Healos, a mineralised collagen product, could eliminate the need to harvest the patient's own bone during spinal surgery, thus reducing hip pain, surgery time and hospital stay. The BAK device is produced by Winterthur-based Sulzer's subsidiary Sulzer Spine-Tech, which holds exclusive worldwide (excluding Japan) marketing rights and distribution rights for Healos. Mountain View, California-based Orquest CE-marked the bone graft last year.
You may also be interested in...
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
Beauty Packaging Producers: July Marks Registration Deadline With PRO In Three States
Companies considered producers of single-use packaging in Oregon, Colorado and California must register with Circular Action Alliance, the leading (and currently only) producer responsibility organization, by 1 July 2024 under new state recycling laws.